-
公开(公告)号:KR100019987B1
公开(公告)日:1985-09-14
申请号:KR1019840004335
申请日:1984-07-21
申请人: 에프. 호프만-라 로슈 아게
IPC分类号: C07D207/27
-
公开(公告)号:KR850000845B1
公开(公告)日:1985-06-17
申请号:KR800003148
申请日:1980-08-08
申请人: HOFFMANN LA ROCHE
发明人: ASHWANDEN WERNER , KYBURZ EMILIO
IPC分类号: C07D207/27 , A61K31/40 , C07D207/26 , C07D207/263 , C07D207/273 , C07F7/10 , C07F7/18
-
公开(公告)号:KR810000657B1
公开(公告)日:1981-06-16
申请号:KR770001822
申请日:1977-08-06
申请人: PFIZER
发明人: NELSON A
IPC分类号: A61K31/40 , C07D207/27
摘要: 1-5-Disubstituted-2-pyrrolidones or their intermediates (I; Q = -C(O)OR3, tetrazol-5-yl, -C(O)NHP4; A is single or cis-double bond; B is single or trans-double bond; U = H OH or HO H; R2 = α -thienyl, phenyl, phenoxy; R3 = H, Cl1-5 alkyl, phenyl or p-biphenyl; R4 = -C(O)R5, -SO2R5; R5 = phenyl, C1-5 alkyl) or alkali or alkali earth metal or ammonium salt contg. C5 epimer or carboxylate or tetrazol-5-yl, having a selective and biological activity, were prepd. by reduction of C15-keto group in the intermediate of pyrrolidone (II). Thus, 5 -(tetrahydropyran-2'-yl oxymethyl-2-pyrrolidone 1 was prepd. from 5-D-hydroxymethylene-2-pyrrolidone, methylene chloride, dihydropyran, p-toluene sulfonic acid.
-
公开(公告)号:KR100009033B1
公开(公告)日:1980-12-16
申请号:KR1019760000705
申请日:1976-03-24
申请人: 스타우퍼케미컬캄파니
发明人: 유우진고우든티이치
IPC分类号: C07D207/27 , C07D207/26
-
公开(公告)号:KR100003475B1
公开(公告)日:1971-04-07
申请号:KR1019670000970
申请日:1967-11-06
发明人: 칼달톤번스호드 , 윌리암존윌스태드주니어 , 그로비크리버랜드헬스리
IPC分类号: C07D207/27
-
公开(公告)号:KR102365673B1
公开(公告)日:2022-02-23
申请号:KR1020187028365
申请日:2017-03-07
IPC分类号: C07D277/14 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/7056 , C07D207/27 , C07D249/08 , C07D277/54 , C07D417/04 , C07D417/10 , C07D417/12 , C07D417/14 , C07H17/02 , A61P1/04 , A61P29/00
摘要: 화학식 (I)의화합물을함유하는오피오이드수용체-관련증상치료용약학조성물이개시된다. 또한, 상기화합물을사용하여오피오이드수용체-관련증상을치료하는방법이개시된다. 화학식 (I)의티아졸리디논화합물두 세트: (i) 각각 90% 초과의거울상이성질체과잉율을갖는화합물, 및 (ii) 각각중수소로치환된화합물이또한개시된다.
-
公开(公告)号:KR20180012788A
公开(公告)日:2018-02-06
申请号:KR20177037062
申请日:2016-05-24
IPC分类号: C07D207/27 , A61K31/4015 , A61P25/08 , C07C53/19 , C07C53/50
CPC分类号: A61K31/4015 , C07C53/19 , C07C53/50 , C07D207/27
摘要: 본발명은거울상이성질체적으로순수한브리바라세탐및 관련유도체의확장가능한합성을제공한다.
摘要翻译: 本发明提供了对映体纯的布立西坦及相关衍生物的可缩放合成。
-
公开(公告)号:KR1020110058002A
公开(公告)日:2011-06-01
申请号:KR1020090114652
申请日:2009-11-25
申请人: 에스케이이노베이션 주식회사 , 에스케이종합화학 주식회사
IPC分类号: C07D207/263 , C07D207/27 , C07D207/267
摘要: PURPOSE: A method for preparing gamma-butarolactone and N-methyl pyrrolidone is provided to save energy and to easily isolate N-methyl pyrrolidone. CONSTITUTION: A method for preparing N-methyl pyrrolidone comprises: a step of performing dehydrogenation of 1,4-butanediol(BDO) under the presence of hydrogen to prepare gamma-butyrolactone; a step of supplying monomethylamine(MMA) solution and gamma-butyrolactone(GBL) in a reactor to isolated N-methyl pyrrolidone(NMP) and water; and a step of mixing the isolated water and MMA to prepare monomethylamine solution.
摘要翻译: 目的:提供制备γ-丁内酯和N-甲基吡咯烷酮的方法,以节省能量并容易地分离N-甲基吡咯烷酮。 构成:制备N-甲基吡咯烷酮的方法包括:在氢存在下进行1,4-丁二醇(BDO)脱氢以制备γ-丁内酯的步骤; 在反应器中将单甲胺(MMA)溶液和γ-丁内酯(GBL)供给到分离的N-甲基吡咯烷酮(NMP)和水中的步骤; 以及将分离的水和MMA混合以制备单甲胺溶液的步骤。
-
公开(公告)号:KR1020090096624A
公开(公告)日:2009-09-11
申请号:KR1020097014182
申请日:2007-12-26
申请人: 산텐 세이야꾸 가부시키가이샤
IPC分类号: C07C275/40 , A61K31/17 , C07D207/27 , A61P27/02
CPC分类号: C07D207/09 , C07C275/24 , C07C275/28 , C07C275/30 , C07C275/34 , C07C275/40 , C07C275/42 , C07C2601/08 , C07C2602/08 , C07C2602/10 , C07D207/27 , C07D211/26 , C07D213/40 , C07D213/75 , C07D215/38 , C07D235/32 , C07D261/14 , C07D277/46 , C07D277/82 , C07D295/12 , C07D307/79 , C07D317/50 , C07D319/18 , C07D333/36 , C07D405/12
摘要: Disclosed are: a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of the pharmacological activity of the derivative. A compound represented by the general formula (1) or a salt thereof has an activity of changing the morphology of a trabecular cell and therefore is effective for the prevention and/or treatment of a disease associated with an ocular tension. In the formula, R1 and R2 independently represents a hydrogen atom, a lower alkyl group or the like; R3 represents a hydroxy group, a lower alkoxy group, a lower cycloalkyloxy group, an aryloxy group or the like; R4 and R5 independently represent a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or the like; X represents a lower alkylene group or the like; Y represents a single bond, a lower alkylene group or the like; l and m independently represent a number of 0, 1, 2 or the like.
摘要翻译: 公开了一种具有尿素结构并由通式(1)表示的新型N-(2-氨基苯基)苯甲酰胺衍生物的合成研究。 并利用衍生物的药理活性。 由通式(1)表示的化合物或其盐具有改变小梁细胞形态的活性,因此对于预防和/或治疗与眼睛张力相关的疾病是有效的。 在该式中,R 1和R 2独立地表示氢原子,低级烷基等; R3表示羟基,低级烷氧基,低级环烷氧基,芳氧基等; R4和R5独立地表示卤素原子,低级烷基,羟基,低级烷氧基等; X表示低级亚烷基等; Y表示单键,低级亚烷基等; l和m独立地表示0,1,2等的数。
-
公开(公告)号:KR100759145B1
公开(公告)日:2007-09-14
申请号:KR1020027010984
申请日:2001-02-21
申请人: 유씨비 파쉼 소시에떼아노님
IPC分类号: C07D207/27
摘要: 본 발명은, 2-옥소-1-피롤리딘 유도체, 이것의 제조 방법 및 이것의 용도에 관한 것이다. 또한, 본 발명은 불포화 2-옥소-1-피롤리딘 유도체로부터 α-에틸-2-옥소-1-피롤리딘 아세트아미드 유도체를 제조하는 방법에 관한 것이다. 특히, 본 발명은 신규한 중간체 및 S-α-2-에틸-옥소-1-피롤리딘 아세트아미드의 제조 방법에서의 이것의 용도에 관한 것이다.
-
-
-
-
-
-
-
-
-